Research platform for children with arthrogryposis multiplex congenita: Findings from the pilot registry.
Noemi Dahan-OlielHarold J P van BosseTanya BedardVasiliki B DarsaklisJudith G HallReggie C HamdyPublished in: American journal of medical genetics. Part C, Seminars in medical genetics (2019)
A pediatric registry for arthrogryposis multiplex congenita (AMC) proposes to advance research by providing the platform to inform the distribution, etiology, and natural history of AMC. The registry was piloted on 40 families of children (mean = 8.25 years, 48% males) presenting with AMC across two hospitals in North America. Data on the child's demographic and newborn variables, mothers' and fathers' demographic variables, lifestyle habits, and medical history were collected using a telephone interview with the primary caregiver and review of medical charts. Mean gestational age was 38 weeks, 97% of children presented with lower extremity deformities, and 74% of neonatal interventions targeted the lower extremity. Newborns spent an average of 14 days in the hospital (range 2-56 days) mostly for diagnostic workup and feeding difficulties. Half (49%) of the sample had internal organ involvement. Genetic testing was done on 48% of the children, including chromosome studies, single gene, whole-exome/genome sequencing, and/or microarray studies. Genetic findings were inconclusive in most. Two-thirds of mothers (67%) reported inconsistently feeling fetal movements. This pilot study contributed to the refinement of participant selection, identification of data source, expansion of data sets, and areas for future exploration prior to the implementation of a multisite AMC pediatric registry.
Keyphrases
- gestational age
- healthcare
- young adults
- high throughput
- electronic health record
- copy number
- birth weight
- preterm birth
- primary care
- big data
- metabolic syndrome
- emergency department
- gene expression
- cardiovascular disease
- clinical trial
- type diabetes
- mental health
- preterm infants
- drug delivery
- study protocol
- current status
- quality improvement
- adverse drug
- real time pcr
- drug induced